Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
BFRI
BFRI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BFRI News
Biofrontera's Ameluz® sNDA Accepted by FDA for sBCC Treatment
4d ago
Newsfilter
BIOFRONTERA INC - FDA Establishes PDUFA Deadline for September 28, 2026
4d ago
moomoo
BIOFRONTERA CONFIRMS FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR AMELUZ® PDT IN TREATING SUPERFICIAL BASAL CELL CARCINOMA
4d ago
moomoo
Biofrontera Reports Positive Phase 3 Trial Results for Ameluz PDT
6d ago
NASDAQ.COM
Biofrontera's Ameluz® Clinical Trial Shows Significant Success
6d ago
Newsfilter
Biofrontera Reports Record Q4 Revenue of $17.5 Million, Driven by Ameluz® Sales
Jan 13 2026
Globenewswire
Baidu Inc Proposes Spinoff of Kunlunxin H Shares, Stock Rises 12.3%
Jan 02 2026
Benzinga
Biofrontera Completes Transfer of Ameluz® NDA and Patents for $11M Investment
Dec 18 2025
Newsfilter
Biofrontera Completes Phase 1 Study of Ameluz®; Plans FDA Submission for 2026
Dec 04 2025
Newsfilter
Biofrontera Inc. Announces Financial Results for Q3 2025 and Offers Business Update
Nov 13 2025
Newsfilter
EXCLUSIVE: Pelthos Acquires Antimicrobial Drug Rights and Raises $18 Million for Commercial Launch Support
Nov 07 2025
Benzinga
Biofrontera Inc. Completes Acquisition of All US Assets for Ameluz® and RhodoLED® from Biofrontera AG
Oct 23 2025
Newsfilter
Biofrontera Inc. Set to Attend Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Sep 26 2025
Newsfilter
Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update
Aug 13 2025
Newsfilter
Biofrontera Inc. Appoints George Jones as Chief Commercial Officer
Aug 11 2025
Newsfilter
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
Aug 08 2025
NASDAQ.COM
Show More News
